Ignite Creation Date:
2025-12-24 @ 5:46 PM
Ignite Modification Date:
2025-12-28 @ 9:36 AM
Study NCT ID:
NCT02749968
Status:
COMPLETED
Last Update Posted:
2022-04-04
First Post:
2016-04-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma
Sponsor:
University of Cincinnati
Organization:
Study Overview
Official Title:
Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma
Status:
COMPLETED
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study of liposomal bupivacaine for pain control in patients with blunt chest wall trauma.
Detailed Description:
The purpose of this study is to evaluate the efficacy of liposomal bupivacaine to provide analgesia via paravertebral intercostal nerve block following significant blunt chest trauma, minimizing adverse outcomes, length of stay and overall narcotic use. The primary outcome of the study is to compare requirements between the bupivacaine group and a standard-of-care group.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: